Prescribing patterns from medical chart abstraction of patients administered lipegfilgrastim: a pilot study in Europe

Figures & data

Figure 1. Flow chart of site recruitment for the pilot study.

Table 1. Demographic and baseline characteristics of patients administered lipegfilgrastim between September 2014 to April 2017.

Characteristics	On-label	Off-label	Missing^a	Total
	(n = 42)	(n = 2)	(n = 2)	(n = 46)
Total patients, n (%)	42 (91.3)	2 (4.3)	2 (4.3)	46 (100)
Age^b, years
Mean (SD)	55 (12.4)	48 (22.6)	N/A	55 (12.7)
Median	54	48		54
IQR: Q1, Q3	47, 64	32, 64		47, 64
Min, max	27, 75	32, 64		27, 75
Age group, n (%)
< 18 years	0	0	0	0
≥ 18 years to < 55 years	22 (52.4)	1 (50.0)	0	23 (50.0)
≥55 years	20 (47.6)	1 (50.0)	0	21 (45.7)
Missing	0	0	2 (100)	2 (4.3)
Sex, n (%)
Female	36 (85.7)	2 (100)	2 (100)	40 (87.0)
Male	6 (14.3)	0	0	6 (13.0)
Country, n (%)
Germany	29 (69.0)	0	0	29 (63.0)
Netherlands	6 (14.3)	2 (100)	2 (100)	10 (21.7)
Belgium	6 (14.3)	0	0	6 (13.0)
Croatia	1 (2.4)	0	0	1 (2.2)
Cancer type, n (%)
Breast	31 (73.8)	2 (100)	1 (50.0)	34 (73.9)
Hodgkin & non-Hodgkin lymphoma	6 (14.3)	0	0	6 (13.0)
Lung	1 (2.4)	0	1 (50.0)	2 (4.3)
Gynecological (except breast)	2 (4.8)	0	0	2 (4.3)
Other	2 (4.8)	0	0	2 (4.3)
Number of lipegfilgrastim treatment cycles per patient
Mean (SD)	2.5 (1.88)	1.0 (0.00)	1.0 (0.00)	2.4 (1.84)
Median	2	1	1	1.5
IQR: Q1, Q3	1, 4	1, 1	1, 1	1, 4
Min, max	1, 10	1, 1	1, 1	1, 10
Use of other G-CSFs prior to lipegfilgrastim first treatment cycle, n (%)
No	19 (45.2)	2 (100)	2 (100)	23 (50.0)
Yes	3 (7.1)	0	0	3 (6.5)
Unknown	20 (47.6)	0	0	20 (43.5)
Number of lipegfilgrastim prefilled syringes used for the first treatment cycle
Mean (SD)	1.0 (0.00)	1.0 (0.00)	1.0 (0.00)	1.0 (0.00)
Median	1	1	1	1
IQR: Q1, Q3	1, 1	1, 10	1 ,1	1, 1
Min, max	1, 1	1, 1	1, 1	1, 1
Dose timing of lipegfilgrastim for the first treatment cycle
Within 24 hours after chemotherapy	35 (83.3)	2 (100)	2 (100)	39 (84.8)
More than 24 hours after chemotherapy	7 (16.7)	0	0	7 (15.2)
Indication for the first treatment cycle^c, n (%)
Neutropenia	36 (85.7)	2 (100)	0	38 (82.6)
Prevention	36 (100)	1 (50.0)	0	37 (97.4)
Treatment	0	0	0	0
Unknown	0	1 (50.0)	0	1 (2.6)
Febrile neutropenia	1 (2.4)	0	0	1 (2.2)
Prevention	1 (100)	0	0	1 (100)
Treatment	0	0	0	0
Other	3 (7.1)	0	0	3 (6.5)
Unknown	5 (11.9)	0	0	5 (10.9)
Prescribing physician specialty^c, n (%)
Oncology	36 (85.7)	2 (100)	0	38 (82.6)
Internal medicine	19 (45.2)	0	0	19 (41.3)
Hematology	15 (35.7)	0	0	15 (32.6)
Pediatrics	1 (2.4)	0	0	1 (2.2)
Other	5 (11.9)	0	0	5 (10.9)
Prescribing physician clinical setting^c, n (%)
Inpatient clinic	30 (71.4)	1 (50.0)	0	31 (67.4)
Outpatient clinic	40 (95.2)	1 (50.0)	0	41 (89.1)

^a Missing information for categorization of on- or off-label due to missing age.

^b Missing age information for two patients.

^c Multiple choices were possible, so categories are not mutually exclusive. Sub-sections under Neutropenia and under Febrile neutropenia use denominators of the total within these two categories.

Note: Percentages may not sum up to 100% due to rounding.

Abbreviations: G-CSF, granulocyte-colony stimulating factor; min, minimum; max, maximum; SD, standard deviation; IQR, interquartile range; Q, quartile; N/A, not applicable.

Table 2. Abstractor assessments for on-label and off-label use during first treatment cycle for the 36 assessable medical records.

Type of use	Abstractor 2
Abstractor 1	On-label use, n	Off-label use, n	Total, n
Type I
On-label use	36	0	36
Off-label use	0	0	0
Total	36	0	36
Type II
On-label use	36	0	36
Off-label use	0	0	0
Total	36	0	36
Type III
On-label use	36	0	36
Off-label use	0	0	0
Total	36	0	36
Type IV
On-label use	33	0	33
Off-label use	3	0	3
Total	36	0	36
Grand total	144	0	144

Type I = Use in children ≤17 years old.

Type II = Use in patients with chronic myeloid leukemia and myelodysplastic syndromes.

Type III = Use in non-cancer patients (e.g. healthy blood donors or patients with human immunodeficiency virus (HIV), congenital, cyclic, or idiopathic neutropenia).

Type IV = Use in cancer patients treated with non-cytotoxic drugs.